Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

VOLUNTARY ANNOUNCEMENT – FIRST PATIENT DOSED IN A PHASE III CLINICAL STUDY OF JSKN016 FOR THE TREATMENT OF TNBC 2026-03-20
VOLUNTARY ANNOUNCEMENT – APPOINTMENT OF CHIEF FINANCIAL OFFICER 2026-03-18
VOLUNTARY ANNOUNCEMENT – FIRST PATIENT DOSED IN A PHASE I CLINICAL STUDY OF JSKN027 2026-03-16
VOLUNTARY ANNOUNCEMENT – IND APPLICATION FOR JSKN021 WAS OFFICIALLY ACCEPTED BY THE CDE 2026-03-13
DATE OF BOARD MEETING 2026-03-11
VOLUNTARY ANNOUNCEMENT – APPOINTMENT OF CHIEF TECHNOLOGY OFFICER 2026-03-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 2026-03-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 2026-02-05
VOLUNTARY ANNOUNCEMENT – NDA FOR FIRST-LINE TREATMENT OF BTC OF KN035 WAS ACCEPTED BY THE NMPA 2026-01-09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 2026-01-06